Hi,
Nobody mentioned the newest deal happened yesterday in US
10.8 B for a clinical-stage biotech is quite a lot of money, imo.
Well, it seems that very good times are coming, once the P2 results (positive) for NNZ2591 will be released
US10.8 bil would mean a price/share of US83 for Neuren (AU$124)
GLTA
Merck acquires Prometheus Biosciences in $10.8bn deal (biopharma-reporter.com)
Merck to acquire Prometheus in a US$ 10.8 b deal
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.35 |
Change
0.520(3.76%) |
Mkt cap ! $1.834B | |||
| Open | High | Low | Value | Volume |
| $13.96 | $14.35 | $13.66 | $6.469M | 457.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2023 | $14.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.38 | 1777 | 1 |
View Market Depth
| Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |